Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Modesto

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Journal of Crohn'S & Colitis|December 8, 2020
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING TrialSéverine Vermeire, Chinyu Su, Nervin Lawendy, et al.
Alimentary Pharmacology & Therapeutics|May 20, 2020
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' replyWilliam J Sandborn, Julian Panés, Bruce E Sands, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2019
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programmeWilliam J Sandborn, Julian Panés, Bruce E Sands, et al.
Therapeutic Advances in Gastroenterology|May 26, 2021
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitisDavid T Rubin, Walter Reinisch, Thomas Greuter, et al.
Inflammatory Bowel Diseases|December 16, 2020
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial DataJeffrey R Curtis, Miguel Regueiro, Huifeng Yun, et al.
Inflammatory Bowel Diseases|June 1, 2022
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving TofacitinibKevin L Winthrop, Séverine Vermeire, Millie D Long, et al.
Gut|July 24, 2020
Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developmentsKlaus Gottlieb, Marco Daperno, Keith Usiskin, et al.
Journal of Crohn'S & Colitis|September 20, 2022
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical ProgrammeWilliam J Sandborn, Geert R D'Haens, Bruce E Sands, et al.
Therapeutic Advances in Gastroenterology|March 3, 2025
Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING studyJoana Torres, Geert R D'Haens, Miguel Regueiro, et al.
Alimentary Pharmacology & Therapeutics|December 2, 2021
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatmentWilliam J Sandborn, Nervin Lawendy, Silvio Danese, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Journal of Crohn'S & Colitis|December 8, 2020
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING TrialSéverine Vermeire, Chinyu Su, Nervin Lawendy, et al.
Alimentary Pharmacology & Therapeutics|May 20, 2020
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' replyWilliam J Sandborn, Julian Panés, Bruce E Sands, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2019
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programmeWilliam J Sandborn, Julian Panés, Bruce E Sands, et al.
Therapeutic Advances in Gastroenterology|May 26, 2021
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitisDavid T Rubin, Walter Reinisch, Thomas Greuter, et al.
Inflammatory Bowel Diseases|December 16, 2020
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial DataJeffrey R Curtis, Miguel Regueiro, Huifeng Yun, et al.
Inflammatory Bowel Diseases|June 1, 2022
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving TofacitinibKevin L Winthrop, Séverine Vermeire, Millie D Long, et al.
Gut|July 24, 2020
Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developmentsKlaus Gottlieb, Marco Daperno, Keith Usiskin, et al.
Journal of Crohn'S & Colitis|September 20, 2022
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical ProgrammeWilliam J Sandborn, Geert R D'Haens, Bruce E Sands, et al.
Therapeutic Advances in Gastroenterology|March 3, 2025
Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING studyJoana Torres, Geert R D'Haens, Miguel Regueiro, et al.
Alimentary Pharmacology & Therapeutics|December 2, 2021
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatmentWilliam J Sandborn, Nervin Lawendy, Silvio Danese, et al.
Pageof 5